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Abstract
Background: There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-
temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main
outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and
to explore its relationship with KD determining whether KD and PIMS are two distinct entities.
Methods: The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients
diagnosed with KD (Kawasaki Disease Group – KDG) or KD-like (Kawacovid Group - KCG) disease between February
1st 2020, and May 31st 2020. Demographic, clinical, laboratory data, treatment information, and patients’ outcome
were collected in an online anonymized database (RedCAP®). Relationship between clinical presentation and SARS-
CoV-2 infection was also taken into account. Moreover, clinical characteristics of KDG during SARS-CoV-2 epidemic
(KDG-CoV2) were compared to Kawasaki Disease patients (KDG-Historical) seen in three different Italian tertiary
pediatric hospitals (Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”, Trieste; AOU Meyer, Florence;
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IRCCS Istituto Giannina Gaslini, Genoa) from January 1st 2000 to December 31st 2019. Chi square test or exact
Fisher test and non-parametric Wilcoxon Mann-Whitney test were used to study differences between two groups.
Results: One-hundred-forty-nine cases were enrolled, (96 KDG and 53 KCG). KCG children were significantly older
and presented more frequently from gastrointestinal and respiratory involvement. Cardiac involvement was more
common in KCG, with 60,4% of patients with myocarditis. 37,8% of patients among KCG presented hypotension/
non-cardiogenic shock. Coronary artery abnormalities (CAA) were more common in the KDG. The risk of ICU
admission were higher in KCG. Lymphopenia, higher CRP levels, elevated ferritin and troponin-T characterized KCG.
KDG received more frequently immunoglobulins (IVIG) and acetylsalicylic acid (ASA) (81,3% vs 66%; p = 0.04 and 71,
9% vs 43,4%; p = 0.001 respectively) as KCG more often received glucocorticoids (56,6% vs 14,6%; p < 0.0001). SARS-
CoV-2 assay more often resulted positive in KCG than in KDG (75,5% vs 20%; p < 0.0001). Short-term follow data
showed minor complications. Comparing KDG with a KD-Historical Italian cohort (598 patients), no statistical
difference was found in terms of clinical manifestations and laboratory data.
Conclusion: Our study suggests that SARS-CoV-2 infection might determine two distinct inflammatory diseases in
children: KD and PIMS-TS. Older age at onset and clinical peculiarities like the occurrence of myocarditis
characterize this multi-inflammatory syndrome. Our patients had an optimal response to treatments and a good
outcome, with few complications and no deaths.
Keywords: SARS-CoV-2, Kawasaki disease, Pediatric inflammatory multisystem syndrome-temporally associated to
SARS-CoV-2 infection, Myocarditis, Hypotension, Multisystem inflammatory syndrome associated with coronavirus
disease, Coronary artery abnormalities
Background
Italy was the first Western Country to be hit by the
SARS-CoV-2 epidemic. To date, more than 236,000
cases have been diagnosed, with more than 32,000
deaths. Children accounted for almost 2% of infections,
with an estimated mortality rate of 0,2% [1]. These data
confirm previous reports on lower rates of SARS-CoV-2
infection and milder forms of the disease in children,
compared to adults [2–4]. Nonetheless, few weeks after
the epidemic peak, an abnormally high number of se-
verely ill children were seen in those areas of the country
with higher SARS-CoV-2 incidence [5–7]; these observa-
tions were then confirmed in other European countries
[8–10]. There is now mounting evidence on the exist-
ence of a childhood multi-inflammatory syndrome re-
lated to SARS-CoV-2 infection sharing some similarities
with Kawasaki Disease (KD) and Toxic Shock Syndrome
(TSS) [9]. This condition has been named such as
Pediatric Inflammatory Multisystem Syndrome-
temporally associated to SARS-CoV-2 infection (PIMS-
TS) or Multisystem Inflammatory Syndrome associated
with Coronavirus Disease 2019 (MIS-C) [11, 12].
However, the real extent of the clinical spectrum of
disease, and the exact role of SARS-CoV-2 infection, are
still poorly understood. Moreover, it is still not clear if
SARS-CoV-2 might also be considered a trigger for KD
development or if KD, during the SARS-CoV-2 epi-
demic, presented peculiar and unusual clinical
manifestations.
Our study aimed to build a national survey for patients
with KD or KD-like multisystemic disease during SARS-
CoV-2 epidemic evaluating clinical manifestations, la-
boratory data, treatment, outcome, and relationship with
virus outbreak.
Methods
Study design and patient selection
This is an observational, retrospective, multicenter study.
Institutional Review Board approval was achieved (IRCC
S Burlo Garofolo-03/2020). The Rheumatology Study
Group of the Italian Pediatric Society launched a na-
tional, online, survey on April 24th, 2020 to enroll those
patients diagnosed with KD or KD-like multisystemic
disease during SARS-CoV-2 epidemic. The children hos-
pitalized between February 1st 2020, and May 31st 2020
with the clinical diagnosis of classical or incomplete-KD
(iKD) as well as KD-like multi-inflammatory syndrome
were enrolled.
The clinical classification was: 1) KD and iKD diagno-
sis, named as Kawasaki Disease Group (KDG), based on
the fulfilment of the American Heart Association criteria
[13]; 2) KD-like multi-inflammatory syndrome diagnosis,
named as KawaCOVID Group (KCG), based on the
presence of i) persistent fever (> 48 h), lymphopaenia
and evidence of single or multi-organ dysfunction with
other additional clinical, laboratory or imagining; ii) ex-
clusion of any other microbial cause [11].
In consideration of the retrospective nature of the
study, an expert panel of pediatric rheumatologists (AR,
GS, CB, MC, RC), blinded for patients’ recruiting center,
was asked to review every patient included in the data-
base to check the correct patient classification or
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eventually reclassify them properly. Those patients who
did not fulfill any of the above-mentioned criteria were
excluded from the study.
Since SARS-CoV-2 spread with different prevalence
through Italy, with Piedmont and Lombardy being the
most heavily hit regions, we also compared the data of
patients from these two regions with the data of patients
from the other regions irrespectively from diagnostic
classification.
At the end, clinical characteristics of KDG during
SARS-CoV-2 epidemic were compared to Kawasaki Dis-
ease patients seen in three different Italian tertiary
pediatric hospitals (Institute for Maternal and Child
Health, IRCCS “Burlo Garofolo”, Trieste; AOU Meyer,
Florence; IRCCS Istituto Giannina Gaslini, Genoa) from
January 1st 2000 to December 31st 2019.
Data collection
Demographic, clinical, and laboratory data, treatment in-
formation, and patient outcome were collected in an on-
line anonymized database which was built for the study
purpose (RedCAP®). Data about complications and last
follow-up after discharge were collected where available.
Results from all tests for SARS-CoV-2 infection with an
RT-PCR assay and/or with a serologic assay were also
reported. Clinical data collected were part of the normal
standard of care.
Statistical analysis
Categorical variables are described as absolute frequency
and percentage while continuous variables as median
and interquartile range. Chi square test or exact Fisher
test were applied to evaluate the association between
two categorical variables while non parametric Wilcoxon
Mann-Whitney test was used to study differences be-
tween two groups of a categorical variable on a continu-
ous variable. A p-value < 0·05 was considered as
statistically significant. Statistical analysis was conducted
using SAS software, Version 9·4 (SAS Institute Inc.,
Cary, NC, USA).
Results
Emails to more than 10,000 members of the Italian
Pediatric Society were sent. Data from 194 patients were
entered into the database. After reviewing all the data
for duplicates and files with missing information 159
cases were sent to the case definition committee. Ten
patients were excluded by the committee since they
didn’t fulfill the inclusion criteria. One hundred forty-
nine patients with a final diagnosis of KDG or KCG were
included in the study. Sixty-nine patients satisfied KD
criteria, 37 iKD criteria, and 43 KawaCOVID criteria.
Among the 37 patients classified as iKD, 10 satisfied also
KawaCOVID criteria and were then associated to the
last group (Fig. 1). The population consisted of 84 males
and 65 females, the median age at the time of diagnosis
was 3 years (IQR: 1–6 years). Sixty-four out of 149 pa-
tients reported at least one symptom in the 3 months
before hospital admittance suggestive for SARS-CoV-2
infection; only one patient (with diarrhea and close con-
tact to a confirmed SARS-CoV-2 patient) had a positive
PCR nasal swab for SARS-CoV-2 1 month before admis-
sion, while 29 patients were tested by nasal swab before
disease onset for close contact with confirmed cases, but
resulted negative.
More than half of the patients (76/149) were from
highly endemic regions (≥30,000 SARS-CoV-2 con-
firmed cases in the general population), while the others
(73/149) came from regions with moderate-low numbers
of SARS-CoV-2 confirmed cases (< 30,000 cases in the
general population). Distribution of KDG and KCG cases
per endemic areas is represented in Fig. 2.
KDG vs KCG at time of diagnosis
KCG children were significantly older (7 years; IQR: 4,5–
11 years vs 2 years; IQR: 1–4 years; p < 0,0001). Skin and
mucosal involvement were more frequent among KDG,
reaching statistical significance. Moreover, the presence
of conjunctivitis was more frequent among KDG as well
as the evidence of irritability. On the other hand, gastro-
intestinal and respiratory involvement were more often
associated to KCG. Clinical manifestations are reported
in details in Table 1 and presence of clinical manifesta-
tions among the two study groups in Fig. 3. ICU admis-
sion was more common in KCG (23,1% vs 1,1%; p < 0,
0001) as well as the occurrence of secondary Hemopha-
gocytic Lymphohistiocytosis (sHLH) (18,4% vs 1,2%; p =
0,001) defined as the presence of HLH-2004 diagnostic
criteria [14]. Median length of hospital stay was 11 days
(IQR: 8–15 days); KCG presented a longer
hospitalization (12 days; IQR: 9–17 days vs 10 days; IQR:
7–14 days; p = 0,02). No death was reported.
KCG presented, moreover, a lower number of leuco-
cytes, lymphocytes, monocytes and platelets, while CRP
was higher in KCG as well as troponin, troponin-T, fer-
ritin and d-dimer (Table 2).
Cardiac involvement
Seventy-seven patients showed heart involvement during
the course of the disease: 35 had myocarditis (60,4%
KCG vs 3,1% KDG; p < 0,0001), 21 pericarditis (26,4%
KCG vs 7,3 KDG; p = 0,0013), 19 valvular insufficiency
(24,5% KCG vs 6,3% KDG; p = 0,0036), 34 coronary ar-
tery abnormalities (CAA) (13,2% KCG vs 28,1% KDG;
p = 0,0427), 20 heart failure (35,8% KCG vs 1% KDG;
p < 0,00001) and 21 hypotension/non-cardiogenic shock
(37,8% KCG vs 1% KDG; p < 0,0001).
Cattalini et al. Pediatric Rheumatology           (2021) 19:29 Page 3 of 11
Data on heart ultrasonography at follow-up was avail-
able for 138 patients out of 149. Median time at follow/
up was 39,9 days (SD ± 20,79) after discharge. Normal
echocardiograms were showed by 77,2% of patients; 15,
4% showed persistent heart ultrasonography abnormal-
ities (15,7% KCG vs 17,2% KDG; p = 1); in details, 6 out
of 8 (75%) KCG still presented persistent mild heart fail-
ure and 2 out of 8 (25%) patients still had valvular insuf-
ficiency; among KDG, 10 out of 15 (66,7%) children had
minimal CAA, 1 patient showed mild pericarditis, 1 pa-
tient heart failure and 3 had valvular insufficiency.
Treatment
One-hundred-twenty-eight patients received intravenous
immunoglobulins (IVIG), 69 (53,9%) glucocorticoids (67
out of them received intravenous glucocorticoids), 123
(99,9%) acetylsalicylic acid (ASA), 4 (3,1%)
Fig. 1 Enrollment of patients flow chart. One hundred fifty-nine patients were initially enrolled; 10 were then excluded form expert panel
revision. Ninety-six patients fitted KD or iKD diagnosis. Ten patients fitted both KD/iKD or Kawacovid criteria while 43 patients filled Kawacovid
criteria. KD=Kawasaki Disease; iKD = incomplete Kawasaki Disease
Fig. 2 SARS-CoV-2 infection and KD/KawaCOVID patients in Italy. Distribution of KDG patients (blue numbers) and KCG (green numbers) in
different areas per SARS-CoV-2 incidence (right squares indicate SARS-CoV-2 number of patients/general population). KDG = Kawasaki Disease
Group; KCG = KawaCOVID Group
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hydroxychloroquine, 9 (7%) patients anakinra and 1 (0,
8%) tocilizumab, 6 (4,7%) anti-viral agents, 93 (72,7%)
antibiotics, 16 (12,5%) vasoactive agents and 27 (21,1%)
heparins. At time of diagnosis IVIG and ASA were used
more frequently in KDG (81,3% vs 66%; p = 0,04 and 71,
9% vs 43,4%; p = 0,001 respectively) while glucocorti-
coids were more often used in patients with KCG (56,6%
vs 14,6%; p < 0,0001). Three patients with KCG received
anti-IL1 treatment (anakinra) and 1 patient hydroxy-
chloroquine. Antiviral treatment was used only in three
patients (2 in the KCG and 1 in KDG), while antibiotics,
vasoactive drugs and heparin were used more frequently
in KCG (73,6% vs 35,4%, p < 0,0001; 20,8% vs 0,0%; p < 0,
0001 and 28,3% vs 1,0%; p < 0,0001 respectively).
Among KCG the use of IVIG alone, glucocorti-
coids alone or combined with IVIG at the time of
diagnosis was not associated with a higher incidence
of clinical worsening (Additional file 1) and/or pres-
ence of cardiac involvement at follow-up (16/106 vs
8/34; p = 0,1).
Table 1 Clinical manifestations at disease onset of KawaCOVID Group (KCG) of patients and Kawasaki Disease Group (KDG) of
patients
KCG (n = 53) N (%) KDG (n = 96) N (%) p value
Skin involvement
Maculo-papular rash 21 (40) 59 (62) 0·001
Erythema multiforme 4 (8) 7 (7) 1
Scarlatiniform rash 0 (0) 8 (8) 0·05
Hands and feet erythema/oedema 15 (28) 38 (40) 0·17
Hands and feet desquamation 1 (2) 6 (6) 0·42
Perineal Erythema/Desquamation 0 (0) 8 (8) 0·05
Mucosal involvement
Cheilitis 14 (26) 46 (48) 0·01
Pharyngeal and/or oral erhytema 24 (45) 49 (51) 0·50
Strawberry tongue 4 (8) 14 (15) 0·29
Ocular involvement
Non Secretive Conjunctivitis 27 (51) 67 (70) 0·02
Neurological involvement
Headache 5 (9) 3 (3) 0·13
Consciousness abnormalities 4 (8) 1 (1) 0·05
Aseptic meningitis 3 (6) 1 (1) 0·13
Irritability 8 (15) 34 (35) 0·01
Gastrointestinal involvement
Diarrhea 28 (53) 11 (12) < 0·0001
Vomiting 14 (26) 8 (8) 0·003
Abdominal pain 17 (32) 10 (10) 0·001
Gallbladder hydrops 2 (4) 3 (3) 1
Respiratory involvement
Dyspnea 8 (15) 1 (1) 0·001
Tachypnea 12 (23) 4 (4) 0·001
Cough 3 (6) 10 (10) 0·38
Rhinitis 0 (0) 5 (5) 0·16
Lobar pneumonia 3 (6) 2 (2) 0·35
Interstitial pneumonia 20 (37) 17 (18) 0·01
O2 supplementation 14 (28) 2 (2) < 0·0001
Ventilation 6 (12) 0 (0) 0·003
Osteoarticular involvement
Arthritis and/or arthralgia 6 (11) 13 (14) 0·7
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Relationship between SARS-CoV-2 infection and
KawaCOVID
One-hundred-thirty-six patients out of 149 were tested
for SARS-CoV-2 with RT-PCR assay and/or with sero-
logic assay. Fifty-four patients resulted positive (14 only
for RT-PCR, 31 only for serologic assay and 9 for both).
The positive assays for SARS-CoV-2 were higher in
KCG (75,5% vs 20%; p < 0·0001).
We compared the data of patients from two regions
with higher SARS-CoV-2 infection (Piedmont and Lom-
bardy) (76 patients) (Group A) with the data of patients
from the other regions (73 patients) (Group B). Group A
patients presented more often with diarrhea (36,8% vs
15,1%; p = 0,003), myocarditis (29,0% vs 9,6%; p = 0,003),
pericarditis (15,8% vs 2,7%; p = 0,01) and hypotension/
non-cardiogenic shock (17,1% vs 2,7%; p = 0,01). Again,
Group A patients were confirmed to be significantly
older (4 years; IQR: 2–8 years vs 2,5 years; IQR: 1–4
years; p = 0,004). Laboratory test showed lower WBC
(11,700/mm3; IQR: 7960–16,900/mm3 vs 16,250/mm3;
IQR: 11180–19,810/mm3; p = 0,03), lymphocytes (1390/
mm3; IQR: 790–2570/mm3 vs 2562,5/mm3; IQR: 1515–
4255/mm3; p = 0,0003) and platelets (225,000/mm3;
IQR: 148000–389,000/mm3 vs 361,000/mm3; IQR:
244000–471,000/mm3; p = 0,01) in group A. Patients
from group A also had higher levels of CRP (195 mg/L;
IQR: 82,2–266,7 mg/L vs 96,6 mg/L; IQR: 40,6–197,9
mg/L; p = 0,003), and higher levels of ferritin (449 ng/
mL; IQR: 227–745 ng/mL vs 218 ng/mL; IQR: 145–458
ng/mL; p = 0,02).
While the KDG cases were spread during the study
period, the KCG cases were mainly concentrated to-
wards the end of the observation period with about 1
month of delay compared to the peak of the SARS-CoV-
2 epidemic (Fig. 4).
Kawasaki disease during SARS-CoV-2 epidemic
Clinical characteristics of KDG during SARS-CoV-2 epi-
demic (KDG-CoV2) were compared to 598 Kawasaki
Disease patients (KDG-Historical) seen in three different
Italian tertiary pediatric hospitals (Institute for Maternal
and Child Health, IRCCS “Burlo Garofolo”, Trieste;
AOU Meyer, Florence; IRCCS Istituto Giannina Gaslini,
Genoa) from January 1st 2000 to December 31st 2019.
No difference was found in age at time of diagnosis,
Female/Male ratio, classical/incomplete Kawasaki Dis-
ease and clinical manifestations (conjunctivitis, lymphoa-
denopathy, cheilitis, skin rash, extremities changes,
Fig. 3 Trend of clinical manifestations among the KawaCOVID Group (KCG) and the Kawasaki Disease Group (KDG)
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sterile pyuria, gastrointestinal involvement, respiratory
symptoms, musculoskeletal symptoms, neurological
symptoms, prevalence of CAA, myocarditis, pericarditis,
and valvular insufficiency) between KDG and KD-
Historical group respectively. No difference was also
found in laboratory data available (Additional files 2 and
3). KDG patients from highly endemic areas (Piedmont
and Lombardy) were compared to those of medium-low
endemic areas. No significant statistical difference was
found in clinical manifestations and laboratory data be-
tween the two groups (Additional files 4 and 5).
Discussion
The occurrence of a severe pediatric inflammatory dis-
ease, with some characteristics of KD, has been de-
scribed since late march, in areas with high SARS-CoV-
2 incidence [5, 7, 9, 15–18]. Whether this is a particu-
larly aggressive form of KD triggered by SARS-CoV-2 or
a completely different entity is still a matter of debate.
Although some case series have already been reported
[15–18], our national survey was aimed to collect all pa-
tients affected by KD and KD-like inflammatory symp-
toms during SARS-CoV-2 epidemic.
Notably, after the first cases of SARS-CoV-2 in the
northern Italy regions, the lock-down policy reduced the
spread of the infection through other regions.
We confirmed some clinical evidence already reported
in the literature; KCG patients are older at disease onset
and present more frequently gastrointestinal and respira-
tory symptoms [3], while the classic mucocutaneous
symptoms of KD were less common. Children in the
KCG also showed higher markers of inflammation, with
Table 2 Laboratory data at disease onset of KawaCOVID Group (KCG) and Kawasaki Disease Group (KDG)





Leucocytes (n/mmc) 11,500 (7310–15,830) 15,730 (11180–19,810) 0·003
Neutrophils (n/mmc) 9156 (6480–14,230) 10,617 (6000–14,780) 0·5
Lymphocytes (n/mmc) 940 (630–1570) 2790 (1680–4340) <·0001
Monocytes (n°/mmc) 320 (160–530) 960 (540–1390) <·0001
Hemoglobin (g/dL) 11,0 (10,1-11,8) 10,8 (10,0–11,7) 0·31
Platelets (n/mmc) 186,000 (132000–292,000) 402,500 (242000–523,000) <·0001
ALT (U/L) 27 (18–63) 29 (18–81) 1
AST (U/L) 36 (20–65) 30 (21–50) 0·56
GGT (U/L) 31 (16–67) 28 (13–59) 0·59
CRP (mg/L) 242 (138,5-300,5) 96,6 (40,6–195) <·0001
IgA (mg/dL) 134,5 (98–150) 83 (48,5-160,5) 0·17
IgG (mg/dL) 857 (655–857) 821 (600–1.106) 0·89
IgM (mg/dL) 90 (75–116) 98,5 (90–152,5) 0·31
Total protein (g/dL) 6 (5,2-6,7) 6,6 (5,9-7,1) 0·03
Albumin (g/dL) 2,9 (2,6-3,5) 3,4 (2,8-3,7) 0·05
CPK (U/L) 57 (32–136) 52 (33–117) 0·55
Troponin-T (ng/L) 82,5 (20–126) 3,5 (3–4) 0·002
Fibrinogen (mg/dL) 643 (515–740) 570,5 (468–714) 0·14
aPTT (ratio) 1,2 (1,0-1,3) 1,1 (1,0-1,2) 0·12
C3 (mg/dL) 139,5 (138–141) 138 (121–196) 0·89
C4 (mg/dL) 27,5 (22–33) 36 (24–46) 0·89
Ferritin (ng/mL) 563,8 (250–1.068) 227 (147–449) 0·0004
D-dimer (ng/mL) 2514 (1.380–3.890) 1740 (730–2.530) 0·03
NT-BNP (pg/mL) 927 (701–1.734) 347 (81–350) 0·08
ESR (mm/hr) 59 (36–81) 66,5 (49,5–98) 0·18
aPTT (sec) 31,7 (30,9-32,4) 26,9 (23–30) 0·16
PT (sec) 14,3 (13,2-15,2) 75,5 (55–88) 0·08
Troponin (ng/L) 168 (80–672) 4 (3–24) 0·001
Triglycerides (mg/dL) 217,5 (137–261) 144,5 (122–196) 0·04
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lower WBC, and platelets [7, 8]. Indeed, lymphopenia is
very common in patients with SARS-CoV-2. Accord-
ingly, patients from the KCG were at higher risk of de-
veloping sHLH which is indeed rarely described in
children with KD [19].
Other authors compared patients with PIMS-TS or an-
alogs with a historic cohort of KD patients obtaining
similar results [7, 9, 16]; the importance of our observa-
tion relies on the fact that out KDG was recruited during
the same period of KCG with a controlled patients
selection.
Patients of the KCG did also require longer time in
the hospital and needed more frequently ICU admit-
tance, for the occurrence of shock, need of vasoactive
agents, and invasive ventilation. In the UK, it has been
recently reported a higher incidence of ICU admittance
of patients with unexplained inflammatory conditions
suggestive of PIMS-TS where 2 out of 78 children died
[20]. No death was reported in our cohort. Although we
did not find any significant correlation between initial
treatment and outcome at the end of follow-up, it is im-
portant to underline that the use of glucocorticoids was
more frequently reported among the KCG and that all
patients among KCG received glucocorticoids, IVIG or
both within 24 h since admission. This is to confirm that
maybe a more aggressive treatment at the time of admis-
sion might prevent clinical complications or even death.
We would suggest, in absence of stronger clinical evi-
dence, that early treatment with both IVIG (2 g/kg/day)
and glucocorticoids (methylprednisone 2 mg/kg/day) is
indicated in KawaCOVID patients; in our experience
treatment with parenteral anakinra (from 2mg/kg/day to
10mg/kg/day) is indicated in those patients with rapid
clinical worsening or if clinical improvement is not
Fig. 4 Relationship between SARS-CoV-2 infection trend and new cases of Kawasaki Disease and KawaCOVID during SARS-CoV-2 infection in Italy
from February 1st 2020 to May 31st 2020
Cattalini et al. Pediatric Rheumatology           (2021) 19:29 Page 8 of 11
reached within 48 h since starting IVIG and corticoste-
roids. Our hypothesis seems to be confirmed from
Navallo-Millan et al., suggesting that anakinra could be
beneficial in COVID-19 adult patients with evidence of
cytokine storm syndrome when initiated early after the
onset of Acute Hypoxic Respiratory Failure [21].
Heart involvement is peculiar to both KDG and KCG
[6, 22]. The major complication in KDG patients was
the occurrence of CAA while KCG patients were at
higher risk to develop myocarditis with heart insuffi-
ciency and related manifestations, such as valvular insuf-
ficiency. One of the main unanswered questions on
PIMS-TS/MIS-C is if patients with this disease are at
risk of developing CAA in the follow/up, as described
for KD. For the first time we were able to provide short-
term follow-up data on our KCG patients, showing that
a minority of patients had minor complications, sequelae
of the acute myocarditis, while the 3 KCG patients that
developed CAA during hospital stay (aneurysms in 2 pa-
tients, dilation in 1), had resolution of the coronary in-
volvement at follow-up. This was in contrast with data
from the KDG, where 10/15 patients still presented at
follow/up with CAA.
Although PIMS-TS and analogs are considered a com-
plication of SARS-CoV-2 infection, the results from nasal
swabs PCR and serologies are usually variable [14, 23].
Data on SARS-CoV-2 exposure were present in 136/149
patients from our cohort. Evidence of SARS-CoV-2 infec-
tion, with limit related to the availability of the text at time
of the study, was more frequent in patients from the KCG.
As already mentioned, SARS-CoV-2 spread with different
incidence through Italy. When comparing patients from
high endemic regions vs patients from low endemic ones,
results were very similar to the analysis of KCG vs KDG,
confirming the hypothesis that KawaCOVID is strictly re-
lated to SARS-CoV-2 infection.
Similar to other reports, there was a 4-weeks delay in
our population between the number of patients with
COVID-19 in the general population and the peak of
KawaCOVID [9]. Very interestingly, while the number
of KawaCOVID cases in the observation period showed
the pattern already described, the number of KD was
constant throughout the same period. KD incidence is
estimated as 5,7 per 100,000 children 0–14 y/o in Italy
[24]. Considering only KD diagnosis, the estimated inci-
dence in our study was 3,99 per 100,000 children < 14y/
o, 5,48/100000 children < 14 y/o considering only pa-
tients from highly endemic regions (Piedmont and Lom-
bardy). Notably, since participation in our registry was
voluntary, cases may have been under-reported.
Since some of our patients with KD had evidence of
SARS-CoV-2 infection, we compared patients from
KDG with a historic cohort of Italian KD patients to bet-
ter define if SARS-CoV-2 could be a trigger of KD and
determine a specific pattern of disease. There was no dif-
ference in clinical or laboratory characteristics and out-
come between the two populations, suggesting that, if
SARS-CoV-2 could trigger KD, it does not determine
specific disease features.
There is still a debate whether KawaCOVID may be
considered a separate clinical entity or a more severe
form of KD [25], specifically triggered by SARS-CoV-2.
The stronger evidence suggesting that PIMS-TS is an se-
vere manifestation of Kawasaki Disease comes from the
remarkable overlapping of many clinical features, mainly
the mucocutaneous manifestations and the possible for-
mation of coronary artery aneurysms. This overlapping
is even more obvious when considering a rare subtype of
KD, described by Kanegaye et al [26] and called Kawa-
saki Shock Syndrome (KSS), whose main feature is the
occurrence of shock. Another important point towards
this hypothesis is the good treatment response to sys-
temic glucocorticoids and IVIG [27].
On the other hand, previous data suggested that pa-
tients with PIMS-TS have some peculiar characteristics
when compared to classic KD patients or even KSS [7,
9]. We suggest that SARS-CoV-2 might determine two
types of inflammatory diseases in children: the first
manifestation is the classic KD, that could be triggered
by the coronavirus, as already suggested [28]. According
to our results, the occurrence of this SARS-CoV-2-trig-
gered KD is rare and does not impact significantly on
the annual incidence of the disease. The second mani-
festation related to SARS-CoV-2 exposure during child-
hood is the multisystem inflammatory syndrome, which
affects older children and presents mainly with myocar-
ditis, gastrointestinal symptoms, and the occurrence of
shock. Since it appears this latter disease is distinct from
KD we recognize the term KawaCOVID could be mis-
leading and both PIMS-TS or MIS-C seem more appro-
priate. Age at SARS-CoV-2 infection, previous
coronaviruses exposure [22], host immunity, and predis-
posing genetics might have a role in determining which
patients would develop a SARS-CoV-2 related disease.
Even though PIMS-TS/MIS-C is a severe disease, the
majority of patients respond to treatments, with few
complications and a good outcome. As prospective data
on larger series are not available, our experience sug-
gests a prompt treatment with glucocorticoids and IVIG.
The use of anakinra is also to take into account if clin-
ical worsening is present or in case of a lack of clinical
response. Ongoing studies on the treatment of inflam-
matory conditions related to SARS-CoV-2 might help to
define the best options for PIMS-TS patients [29].
Conclusions
Our study suggests that SARS-CoV-2 infection is the
causative agent of PIMS-TS in children. Older age at
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onset and clinical peculiarities like the occurrence of
myocarditis characterize this multi-inflammatory syn-
drome which share specific clinical manifestations with
KD. Our patients had an excellent response to treatment
and a good outcome, with few complications and no
deaths.
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